Effectiveness of 8 ‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

ConclusionsIn treatment‐naïve HCV genotype 1 patients, SVR was 95% in those treated for either 8 weeks or 12 weeks with ledipasvir and sofosbuvir. 8 week ledipasvir and sofosbuvir can reduce costs without compromising outcomes for those patients who qualify for such regimen.

Source: Alimentary Pharmacology and Therapeutics - July 10, 2017 Category: Drugs & Pharmacology Authors: M. P. Curry, E. B. Tapper, B. Bacon, D. Dieterich, S. L. Flamm, L. Guest, K. V. Kowdley, Y. Lee, S. Milligan, N. Tsai, Z. Younossi, N. H. Afdhal Tags: ORIGINAL ARTICLE Source Type: research